T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) Reviewed for Therapeutic Pipeline Development- H1 2017

Published on : Jul 06, 2017

Albany, New York, July 6, 2017: The functionality of the T Lymphocyte Activation Antigen CD80 as a coreceptor activity and virus receptor activity helps in its growth and development. To analyze the related therapeutic development and assessment, Market Research Hub (MRH) has recently added a researched study titled as “T Lymphocyte Activation Antigen CD80 (Activation B7-1 Antigen or CTLA 4 Counter Receptor B7.1 or CD80) - Pipeline Review, H1 2017” to its vast report repository.

The T lymphocyte activation antigen is a cluster of differentiation 80 or CD80 or B7-1. It is a protein found on dendritic cells, activated B cells and monocytes. The activated protein induces T-cell proliferation and cytokine production. T-cell proliferation and cytokine production are induced by the binding of CD28. This detailed report primarily covers products from therapy areas including Immunology, Musculoskeletal Disorders, Oncology, Cardiovascular, Dermatology, Gastrointestinal, Genito-Urinary System And Sex Hormones, Metabolic Disorders, and Ophthalmology which include indications Rheumatoid Arthritis, Autoimmune Disorders, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alopecia, Breast Cancer, and other.

The research commences with the T lymphocyte activation antigen CD80 brief overview, along with its therapeutic development, assessment and companies involved. The therapeutic development detail the products under development by stage of development, therapy area, indication, companies and by universities/colleges. Furthermore, the related therapeutic assessment shows the various CD80 assessment which includes mechanism of action, by route of administration and by molecule type. The detailed study also features the major companies involved in the provided therapeutic development. The major key players include; 3SBio Inc, BioAtla LLC, Bristol-Myers Squibb Company, KAHR Medical Ltd, MediGene AG, MedImmune LLC, and Momenta Pharmaceuticals Inc.

The following section also profiles the main drugs under T lymphocyte activation antigen CD80 therapeutic development. The various featured drugs are abatacept, abatacept biosimilar, CUE-201, KAHR-102, KN-019, MEDI-5265, Monoclonal Antibody to Inhibit CTLA-4 for Oncology, RhuDex, Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer, and Vaccine to Target CD80 & IL-2 for Acute Myeloblastic Leukemia. Moreover, a brief introduction of the dormant products, the discontinued products and the featured news and press releases are provided in the intelligent research for complete evaluation. The research concludes by providing and thus validating the various resourceful data along with the numerous tables and figures that help in portraying the pictorial representation of the discussed industry and helping in efficient decision making by the experts.

Click here to get more info with TOC in a PDF Format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1157716

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top